Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) Net Margin (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Net Margin for 3 consecutive years, with 174.23% as the latest value for Q1 2025.

  • On a quarterly basis, Net Margin changed N/A to 174.23% in Q1 2025 year-over-year; TTM through Sep 2025 was 1617.99%, a 789289.0% decrease, with the full-year FY2023 number at 2204.65%, changed N/A from a year prior.
  • Net Margin was 174.23% for Q1 2025 at Centessa Pharmaceuticals, down from 1433.35% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 3911.74% in Q2 2022 to a low of 174.23% in Q1 2025.
  • A 3-year average of 2029.68% and a median of 1960.63% in 2022 define the central range for Net Margin.
  • Biggest YoY gain for Net Margin was -52728bps in 2023; the steepest drop was -289598bps in 2023.
  • Centessa Pharmaceuticals' Net Margin stood at 1960.63% in 2022, then fell by -27bps to 1433.35% in 2023, then plummeted by -112bps to 174.23% in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Net Margin are 174.23% (Q1 2025), 1433.35% (Q4 2023), and 1520.98% (Q3 2023).